REPORT ID 13681

Global Hemophilia Gene Therapy Market Size, Status and Forecast 2022

Publish Date
22-Nov-17
Pages
97
Format
Electronic (PDF)

This report studies the global Hemophilia Gene Therapy market, analyzes and researches the Hemophilia Gene Therapy development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like
    Novo Nordisk A/S?
    Pfizer Inc.?
    F. Hoffmann-La Roche Ltd.?
    Bayer AG?
    Shire plc?
    CSL Limited?
    Octapharma AG?
    Grifols International SA?
    Swedish Orphan Biovitrum AB?
    Alnylam Pharmaceuticals, Inc.?

Market segment by Regions/Countries, this report covers
    United States
    EU
    Japan
    China
    India
    Southeast Asia

Market segment by Type, Hemophilia Gene Therapy can be split into
    Hemophilia A?
    Hemophilia B?
    Others?

Market segment by Application, Hemophilia Gene Therapy can be split into
    Hospital
    Clinic


 
			   
Table of Contents

Global Hemophilia Gene Therapy Market Size, Status and Forecast 2022
1 Industry Overview of Hemophilia Gene Therapy
    1.1  Hemophilia Gene Therapy Market Overview
        1.1.1 Hemophilia Gene Therapy Product Scope
        1.1.2 Market Status and Outlook
    1.2 Global Hemophilia Gene Therapy Market Size and Analysis by Regions
        1.2.1 United States
        1.2.2 EU
        1.2.3 Japan
        1.2.4 China
        1.2.5 India
        1.2.6 Southeast Asia
    1.3 Hemophilia Gene Therapy Market by Type
        1.3.1 Hemophilia A?
        1.3.2 Hemophilia B?
        1.3.3 Others?
    1.4 Hemophilia Gene Therapy Market by End Users/Application
        1.4.1 Hospital
        1.4.2 Clinic

2 Global Hemophilia Gene Therapy Competition Analysis by Players
    2.1 Hemophilia Gene Therapy Market Size (Value) by Players (2016 and 2017)
    2.2 Competitive Status and Trend
        2.2.1 Market Concentration Rate
        2.2.2 Product/Service Differences
        2.2.3 New Entrants
        2.2.4 The Technology Trends in Future

3 Company (Top Players) Profiles
    3.1 Novo Nordisk A/S?
        3.1.1 Company Profile
        3.1.2 Main Business/Business Overview
        3.1.3 Products, Services and Solutions
        3.1.4 Hemophilia Gene Therapy Revenue (Value) (2012-2017)
        3.1.5 Recent Developments
    3.2 Pfizer Inc.?
        3.2.1 Company Profile
        3.2.2 Main Business/Business Overview
        3.2.3 Products, Services and Solutions
        3.2.4 Hemophilia Gene Therapy Revenue (Value) (2012-2017)
        3.2.5 Recent Developments
    3.3 F. Hoffmann-La Roche Ltd.?
        3.3.1 Company Profile
        3.3.2 Main Business/Business Overview
        3.3.3 Products, Services and Solutions
        3.3.4 Hemophilia Gene Therapy Revenue (Value) (2012-2017)
        3.3.5 Recent Developments
    3.4 Bayer AG?
        3.4.1 Company Profile
        3.4.2 Main Business/Business Overview
        3.4.3 Products, Services and Solutions
        3.4.4 Hemophilia Gene Therapy Revenue (Value) (2012-2017)
        3.4.5 Recent Developments
    3.5 Shire plc?
        3.5.1 Company Profile
        3.5.2 Main Business/Business Overview
        3.5.3 Products, Services and Solutions
        3.5.4 Hemophilia Gene Therapy Revenue (Value) (2012-2017)
        3.5.5 Recent Developments
    3.6 CSL Limited?
        3.6.1 Company Profile
        3.6.2 Main Business/Business Overview
        3.6.3 Products, Services and Solutions
        3.6.4 Hemophilia Gene Therapy Revenue (Value) (2012-2017)
        3.6.5 Recent Developments
    3.7 Octapharma AG?
        3.7.1 Company Profile
        3.7.2 Main Business/Business Overview
        3.7.3 Products, Services and Solutions
        3.7.4 Hemophilia Gene Therapy Revenue (Value) (2012-2017)
        3.7.5 Recent Developments
    3.8 Grifols International SA?
        3.8.1 Company Profile
        3.8.2 Main Business/Business Overview
        3.8.3 Products, Services and Solutions
        3.8.4 Hemophilia Gene Therapy Revenue (Value) (2012-2017)
        3.8.5 Recent Developments
    3.9 Swedish Orphan Biovitrum AB?
        3.9.1 Company Profile
        3.9.2 Main Business/Business Overview
        3.9.3 Products, Services and Solutions
        3.9.4 Hemophilia Gene Therapy Revenue (Value) (2012-2017)
        3.9.5 Recent Developments
    3.10 Alnylam Pharmaceuticals, Inc.?
        3.10.1 Company Profile
        3.10.2 Main Business/Business Overview
        3.10.3 Products, Services and Solutions
        3.10.4 Hemophilia Gene Therapy Revenue (Value) (2012-2017)
        3.10.5 Recent Developments

4 Global Hemophilia Gene Therapy Market Size by Type and Application (2012-2017)
    4.1 Global Hemophilia Gene Therapy Market Size by Type (2012-2017)
    4.2 Global Hemophilia Gene Therapy Market Size by Application (2012-2017)
    4.3 Potential Application of Hemophilia Gene Therapy in Future
    4.4 Top Consumer/End Users of Hemophilia Gene Therapy

5 United States Hemophilia Gene Therapy Development Status and Outlook
    5.1 United States Hemophilia Gene Therapy Market Size (2012-2017)
    5.2 United States Hemophilia Gene Therapy Market Size and Market Share by Players (2016 and 2017)

6 EU Hemophilia Gene Therapy Development Status and Outlook
    6.1 EU Hemophilia Gene Therapy Market Size (2012-2017)
    6.2 EU Hemophilia Gene Therapy Market Size and Market Share by Players (2016 and 2017)

7 Japan Hemophilia Gene Therapy Development Status and Outlook
    7.1 Japan Hemophilia Gene Therapy Market Size (2012-2017)
    7.2 Japan Hemophilia Gene Therapy Market Size and Market Share by Players (2016 and 2017)

8 China Hemophilia Gene Therapy Development Status and Outlook
    8.1 China Hemophilia Gene Therapy Market Size (2012-2017)
    8.2 China Hemophilia Gene Therapy Market Size and Market Share by Players (2016 and 2017)

9 India Hemophilia Gene Therapy Development Status and Outlook
    9.1 India Hemophilia Gene Therapy Market Size (2012-2017)
    9.2 India Hemophilia Gene Therapy Market Size and Market Share by Players (2016 and 2017)

10 Southeast Asia Hemophilia Gene Therapy Development Status and Outlook
    10.1 Southeast Asia Hemophilia Gene Therapy Market Size (2012-2017)
    10.2 Southeast Asia Hemophilia Gene Therapy Market Size and Market Share by Players (2016 and 2017)

11 Market Forecast by Regions, Type and Application (2017-2022)
    11.1 Global Hemophilia Gene Therapy Market Size (Value) by Regions (2017-2022)
        11.1.1 United States Hemophilia Gene Therapy Revenue and Growth Rate (2017-2022)
        11.1.2 EU Hemophilia Gene Therapy Revenue and Growth Rate (2017-2022)
        11.1.3 Japan Hemophilia Gene Therapy Revenue and Growth Rate (2017-2022)
        11.1.4 China Hemophilia Gene Therapy Revenue and Growth Rate (2017-2022)
        11.1.5 India Hemophilia Gene Therapy Revenue and Growth Rate (2017-2022)
        11.1.6 Southeast Asia Hemophilia Gene Therapy Revenue and Growth Rate (2017-2022)
    11.2 Global Hemophilia Gene Therapy Market Size (Value) by Type (2017-2022)
    11.3 Global Hemophilia Gene Therapy Market Size by Application (2017-2022)

12 Hemophilia Gene Therapy Market Dynamics
    12.1 Hemophilia Gene Therapy Market Opportunities
    12.2 Hemophilia Gene Therapy Challenge and Risk
        12.2.1 Competition from Opponents
        12.2.2 Downside Risks of Economy
    12.3 Hemophilia Gene Therapy Market Constraints and Threat
        12.3.1 Threat from Substitute
        12.3.2 Government Policy
        12.3.3 Technology Risks
    12.4 Hemophilia Gene Therapy Market Driving Force
        12.4.1 Growing Demand from Emerging Markets
        12.4.2 Potential Application

13 Market Effect Factors Analysis
    13.1 Technology Progress/Risk
        13.1.1 Substitutes
        13.1.2 Technology Progress in Related Industry
    13.2 Consumer Needs Trend/Customer Preference
    13.3 External Environmental Change
        13.3.1 Economic Fluctuations
        13.3.2 Other Risk Factors

14 Research Finding/Conclusion

15 Appendix
    Methodology
    Analyst Introduction
    Data Source